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The TD50: A Proposed General Convention
for the Numerical Description of the
Carcinogenic Potency of Chemicals in
Chronic-Exposure Animal Experiments
by Richard Peto,* Malcolm C. Pike,*t Leslie Bernstein,t
Lois Swirsky Gold* and Bruce N. Ames**
A generally accepted format for the numerical description of the carcinogenic potency of a particular
chemical in a particular strain of animals is desirable so that statements from different sources about
potency and attempts by different authors to correlate potency with particular laboratory measurements
will be comparable. The choice of an appropriate standard format is to a certain extent arbitrary. In this
paper we recommend that the TD50 (tumorigenic dose rate 50) be used. TD50 can be calculated for a single
target site or combination ofsites. TheTD50, in analogy with the LD50, is defined as that chronic dose rate
(in mg/kg body weight/day) which would halve the actuarially adjusted percentage oftumor-free animals at
the end of a standard experiment time-the "standard lifespan" for the species. This paper consists of a
brief discussion ofthe TD50, sufficient to make the general reader familiar with the properties of such an
index, an appendix discussing methods for its estimation and certain conventions we have adopted for use
in analyzing "nonstandard" experiments. A major problem in calculating any index of carcinogenic
potency is that much published material gives only the final crude percentage oftumor-bearing animals at
each dose, instead of percentages adjusted for the effects of intercurrent mortality or data from which
these adjusted percentages can be derived. If the dose level administered to the animals is toxic, then
premature death from nonneoplastic causes may prevent some dosed animals that would have developed
tumors from actually doing so. This will particularly affect the high-dose group. Consequently, any
estimate of carcinogenic potency that is based on crude percentages of tumor-bearing animals, not
adjusted for intercurrent mortality, may underestimate the carcinogenicity of the test material.
A Numerical Index: the TD50
For various purposes, such as a quantitative compari-
son of the results from carcinogenicity experiments
with results from various in vitro tests, a numerical
index of carcinogenic potency must be estimated from
animal carcinogenicity data. Many ad hoc indices can be
proposed, none clearly superior to all others. In this
situation, it would clearly be desirable if most workers
would generally adopt the same index, and we propose
that, by convention, a particular numerical measure of
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carcinogenic potency (the TD50) be adopted as this
standard index.
In classical acutetoxicology, the LD50 (lethal dose 50)
of a chemical is defined as that dose of the chemical
which kills 50% ofthe test animals. A large value forthe
LD50 indicates, of course, a substance of low acute
toxicity, while a small LD50 indicates a very potent
poison. Although the LD50 varies with strain, species
and experimentalconditions, it has proved tobe auseful
and practical measure of acute toxicity, and is widely
used and understood. In order to adopt some roughly
analogous measure for the tumorigenicity of a particu-
lar agent, the TD50 will be defined as the tumorigenic
dose rate for 50% of the test animals, i.e., for a given
target site(s), the TD50 is that chronic dose rate (in
mg/kg body weight/day) which would give half of the
animals tumors within some standard experiment time
-the "standard lifespan" for the species. There are,
however, three points that must be clarified before such
a definition of the TD50 is possible.PETO ET AL.
First, how is the TD50 to be defined if some of the
control animals also get tumors? The most natural
definition to adopt seems tobe thatthe TD50is thatdose
ratewhichhalvestheprobabilityofremainingtumorless
tothe endofthe standard lifespan. Usingthisdefinition,
if20% ofthe controls get the tumor(s) ofinterest, then
the TD50 willbe the doseratethat leadstoatotalof60%
of the treated animals developing that tumor. This
definition is analogous to that proposed for LD50 when
deaths occur in the the control group (1,2). It obviously
makes good sensewhenthe spontaneous andtreatment-
related tumors arise by independent mechanisms, but it
does not implicitly assume that this is the case.
Second, some tumors are observed in a"fatal" context
(i.e., they are the direct orindirect cause ofthe death of
their host), while others are observed only in an
'incidental" context (i.e., they do not cause the death of
their host, and are discovered only because the host has
been sacrificed, has died of nonneoplastic treatment
toxicity, or has died of some unrelated disease). By
convention, in defining the TD50, we shall count all
animals bearing the tumor of interest, irrespective of
whether their tumors were observed in a fatal or in an
incidental context. We have discussed at length else-
wherethestatisticalrelevance ofthedistinctionbetween
incidental and fatal tumors (3). Here, however, we are
concerned only with the biological question ofwhether,
after30% ofa group ofanimals have died as aresult ofa
given type oftumor and a further 30% ofthe group are
already carrying such tumors but are still alive, we
define the proportion oftumorless animals to be 70% or
40%. To us the latter seems preferable, since otherwise
we would be forced to ignore all ofthe information that
is found when an experiment is terminated and the
survivors are autopsied. When substantial numbers of
terminally sacrificed animals have internal tumors that
are detectable only at autopsy, the "incidental" tumors
found may well provide more information than all ofthe
earlierfindings put together. Moreover, to descend from
thetheoretical to the practical, the information as tothe
context in which tumors are observed is, with the
exception of terminal sacrifice, rarely recorded or
published.
Third, most types of cancer are typically diseases of
old age, and premature deaths from other causes will
prevent some cases of cancer that would have arisen in
old age from actually doing so. Intercurrent mortality is
a moderate nuisance in experiments with "nontoxic"
doses of carcinogens (i.e., carcinogens administered at
dose levels that do not materially affect nonneoplastic
causes of death), and may be a serious nuisance in
experiments with toxic carcinogens, where more high-
doseanimalsthancontrolsdieprematurelyfromnonneo-
plastic causes. Papers reporting that the crude percent-
age of animals which develop tumors was decreased at
high dose(s) are probably reporting artifacts that are
due tofailure tomake proper allowance forthe effects of
competing risks on tumor yields (3). The definition of
the TD50 should therefore be based not on the crude
percentages ofanimals that develop tumors, but rather
on some estimate of the percentages of animals that
would have done so had intercurrent mortality been
prevented.
There are various ways in which these mortality-
corrected probabilities may be estimated. Ideally, one
might first estimate the proportion of animals that
would still be alive at the end ofthe standard lifespan if
all causes of death other than the tumor type(s) of
interest were prevented, then estimate the proportion
ofthe survivors at the end ofthe standard lifespan that
are free ofoccult tumors ofthe type(s) ofinterest, and
finally multiply these two proportions together. In
practice, few, if any, experiments provide the full data
that are needed to achieve this. If such detailed
time-to-tumor data are available, the least unsatisfac-
tory approximation in many instances seems to be to
use "actuarial," or "death-rate" methods (3) on all
tumors. These methods are exactly appropriate for
premature deaths as a result of the tumor type of
interest and are algebraically equivalent to prevalence
methods for all tumors found at terminal sacrifice, but
lead tosome overestimation ofthe finaltumoryieldwhen
there are many premature deaths at which incidental
tumors are found. In some instances, however, espe-
cially when the tumors that arise are principally lesions
thatareconsideredunlikelytohavebeenfatal, "prevalence-
rate" methods (3) for all neoplasms may instead be
preferred. In principle, an appropriate combination of
death-rate and prevalence-rate methods can be used for
TD50 estimation; in practice, this should be done only
when sufficiently extensive data on prevalence rates are
available for gross numerical instabilities to be avoided.
Although we give details in the Appendix of certain
statistical procedures we have adopted for estimating
the TD50 from experimental data in our Carcinogenic
Potency Database described in the accompanying paper
(4), these procedures are not intended to be part of its
definition and other statistical procedures may be
employed.
Definition
For any particular sex, strain, species and set of
experimental conditions, the TD50 is the dose rate (in
mg/kg body weight/day) that, if administered chroni-
cally for a standard period-the "standard lifespan" of
the species-will halve the mortality-corrected esti-
mate ofthe probability ofremainingtumorless through-
out that period.
As defined, a TD50 can be computed either for a
particular category ofneoplastic lesion (e.g. "malignant
tumors only," "liver tumors only," etc.) orforall tumors.
There is no need for absolute uniformity in this, for on
different occasions, different tumorcategories will be of
interest. In the absence of any special overriding
considerations, we propose that the category studied
should be either "those tumor types that are strongly
affected by treatment" or "all tumor types, benign or
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malignant"* If treatment strongly affects some tumor
types and has no material effect on any others, then use
of either of these two categories will usually yield
approximately the same TD50. When estimating aTD50
from published reports that do not give details of the
exact category of tumors one would like to study, it is
necessary to choose from those tumor categories that
are adequately documented. It may then be best to
study "the category of tumors that are statistically
significantly related to treatment," despite the bias
which this can in principle cause. In our analyses of
chemicals tested in the Carcinogenesis Bioassay Pro-
gram ofthe National Cancer Institute/National Toxicol-
ogy Program (NCI/NTP) given in the accompanying
paper, we have generally utilized analyses ofindividual
categories oftumors considered to be treatment-related
in the NCI/NTP reports, the aggregate of all sites
considered to be treatment-related in the NCI/NTP
reports, and all tumor-bearing animals (TBAs) exclud-
ing only testis tumors in F344 rats. For the general
published literature we have used TBAs and individual
sites, but lack the data to aggregate the treatment-
related sites.
Why the TD50 Rather Than Some
Other Index of Potency?
Indices such as the TD10 or TD90 can be defined and
are probably as good as the TD50 if they can be as
reliably estimated. One advantage of the TD50 is that
the experimental dose range will often include it, which
makes for statistically accurate estimation. Also, there
is the useful analogy with the LD50.
An alternative to the TD50 might be the "doubling
dose" for some category of tumors, i.e., the dose rate
needed to double the spontaneous tumor rate. The
advantage of this index is that it might on theoretical
grounds, although not on any direct evidence, be
expected to be more reproducible in different species.
The overwhelming disadvantage of using a doubling
dose to characterize experimental data is that the
spontaneous frequency of most tumors is difficult to
characterize accurately, and so, estimated doubling
doses would be subject to severe sampling errors.
possible, but it is unclear how they propose allowing for
the percentage of tumors in the control groups.
Crouch and Wilson (6) proposed an index of potency
which will in practice often be closely correlated with
the TD50, but where noteworthy discrepancies do exist,
the TD50 is preferable. Formally, Crouch and Wilson
assumed that -In (1-P) = a + bd, P being the
proportion developing tumors at dose rate d and a and b
being constants to be estimated from the data. If this
model fitted the data and P were corrected for intercur-
rent mortality, Meselson and Russell (5) would estimate
the carcinogenic potency as b, and we would estimate
theTD50as0.693/b. Crouch andWilson, however, ignore
the possibility of correction for intercurrent mortality,
and define potency not as b but as b exp [-a]. This latter
conventionisinprinciplesomewhatunsatisfactorybecause
itissystematicallybiasedbytheoccurrence ofspontane-
ous tumors by mechanisms unrelated to the carcino-
genic effects ofthe test agent. The bias is by a factor of
exp [-a] so that in practice it is important only when the
spontaneous frequency, 1 - exp [-a], oftumors is large.
Finally, the National Academy of Sciences' Commit-
tee on Prototype Explicit Analyses for Pesticides (7)
defined a Carcinogenic Activity Indicator (CAI) for
each dose group in a particular experiment by CAI =
"percentresponse" . dose, wherethe"percentresponse"
is the difference between the mortality-corrected (life-
table) percentages of tumor-bearing animals in the
treated and control groups. The CAIs calculated from
each treatment group willusually be different and these
differences will depend systematically on the dose level
that was tested. (Even ifthey do not do so at low doses
they must do so at high doses, since the excess
percentage affected cannot exceed 100%.) This makes
the CAI somewhat unsatisfactory. These problems
could be avoided by specifying that the CAI to be used
for a chemical is the CAI at that dose which gives half
the animals tumors, or halves the probability ofremain-
ing tumorless. The CAI would then fairly closely
resembletheTD50, exceptthatintheproposed definition
ofthe CAI no explicit account was taken ofthe duration
ofthe study. The CAI, like Crouch and Wilson's potency
index, is also systematically biased by variations in the
frequency of spontaneous tumors. Thus, although the
CAI will generally be quite closely correlated with the
TD50, where discrepancies arise the TD50 is preferable.
Indices Proposed by Other Authors Confidence Intervals
Meselson and Russell (5) defined an index ofcarcino-
genic potency, which in the absence of intercurrent
mortality is equivalent to In 2/TD50 (i.e., to about
0.693/TD50). The description of the method of calculat-
ing the index given in their paper clearly shows that
they adjust for intercurrent mortality, when this is
*Except, perhaps, for one or a few prespecified types oftumor that
have such a high spontaneous frequency that they would swamp the
data (e.g., interstitial-cell testis tumors in male Fischer F344 rats, a
neoplasm that eventually affects almost all such animals).
The TD50 estimated from a particular experiment is
subject to the usual statistical uncertainties, and it is
usually useful to estimate a confidence interval about it.
Invariably, there will also be nonstatistical uncertain-
ties in the conduct ofany experiment, and this suggests
that a wide statistical confidence interval will be more
"realistic"; werecommendthata99%confidencecoefficient
be used rather than the more usual 95%. In an
experiment where the statistical significance ofTD50 is
p < 0.01 (two-tailed), the confidence interval will be
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two-sided: for example, a 99% confidence interval of 1.5
to 6.7 mg/kg body weight/day for the TD50 would
suggest that (in the absence of other causes of death)
1.5 mg/kg body weight/day would not halve the propor-
tion of tumorless survivors at the end of the standard
lifespan, while 6.7 mg/kg body weight/day would more
than halve it.
In an experiment where the statistical significance of
TD50isp > 0.01 (two-tailed), the confidence interval for
the TD50 will be open at one end; for example, a
confidence interval with a lower limit of 10 mg/kg body
weight/day for the TD50 and no upper limit suggests
that 10 mg/kg body weight/day would probably (in the
absence of other causes' of death) fail to halve the
proportion oftumorless survivors, but makes no definite
statement about the carcinogenic effects of higher
doses. The results from a statistically nonsignificant (p
> 0.01) experiment thus give a lower limit to the TD50,
but do not demonstrate noncarcinogenicity. A fuller
discussion ofthe meaning and proper uses ofp-values is
given elsewhere (3).
TD50 Estimated, with Bias,
from Unadjusted Percentages
of Tumor-Bearing Animals
In chronic carcinogenicity studies, the cancers that
arise often do so quite late in the lifespan ofthe animals
concerned. As has already been noted, the number of
animals that eventually develop cancer at any one
particular age therefore depends on the number of
animals that survive to that age (which may be reduced
by intercurrent mortality to a different extent in each
treatment group), as well as on the proportion ofthese
survivors that will then develop new tumors in the near
future. "Actuarial" (life-table) analysis overcomes the
gross effects ofmortalityt from other causes by estimat-
ing the number of animals that would have developed
tumors if, hypothetically, all nonneoplastic deaths had
been prevented. This analysis is the method that we
have used in our Carcinogenic Potency Database when
time-to-tumor data are available.
In many positive carcinogenicity bioassays, the non-
neoplastic toxicity of the highest administered dose
causes sufficient early deaths to reduce quite substan-
tially the proportion of animals that survive long
enough to develop cancer. On occasion, this effect is so
extreme that the proportion of animals that get cancer
before they die is actually lower in the group given the
highest dose of carcinogen than in lower dose groups.
tAs already noted, precise correction requires that a distinction be
made between tumors observed in an incidental and in a fatal context,
and this information is not generally available in present-day experi-
mental reports, let alone in the past literature. Although the
inappropriate use of actuarial methods for incidental neoplasms may
somewhat overcorrect for the effects of intercurrent mortality on
tumor yields, it may nevertheless be the best technique to use in
practice (see above and the appendix).
Although there is likely to be a fairly direct relationship
between carcinogenicity and the actuarially adjusted
percentages oftumor-bearing animals, the relationship
between carcinogenicity and the crude, unadjusted,
percentages of tumor-bearing animals may thus be
distorted or even inverted. Estimation of the TD50 (or
any other numerical potency index) from crude unad-
justed data may therefore underestimate the carcinoge-
nicity of the test material. Although confidence inter-
vals can be derived for the effects of random variation
on a TD50 estimated from crude percentages, the
systematic bias caused by intercurrent mortality cannot
usually be quantified. If estimated from data on crude
unadjusted percentages, the TD50 and its confidence
limits will tend to be too high, underestimating the true
potency of the chemical.
Whether or not authors of future carcinogenicity
studies choose to estimate and to include in their
published reportsTD50values (withconfidence intervals)
for the substances they study, it is important that they
publish their data in sufficient detail to permit others to
make allowance for intercurrent mortality. Lack ofsuch
data is a serious impediment to the accurate interpreta-
tion of many past studies (3).
Conclusion
The accompanying paper (4) provides a graphic dis-
play of the TD50 values (and associated confidence
intervals) for all carcinogenicity tests reported before
mid-1980 by the NCI/NTP Bioassay Program and for
the long-term experiments from the published litera-
ture through mid-1981 that meet our standard criteria
for selecting "suitable" tests.
As cancer research progresses, it will presumably be
possible to account for more and more of the unex-
plained differences between the TD50 values observed in
different carcinogenicity studies. Whether or not much
immediate progress is possible, we hope that the plot of
TD50 values which is provided in the accompanying
paper will provoke more interest in the quantitative
aspectsofchemicalcarcinogenesis thancurrentlyexists.
Ifnothing else, the database emphasizes how enormous
the range of potency is; some weak carcinogens have a
TD50 of over 1000 mg/kg body weight/day while others
have a TD50 ofunder 0.001 mg/kgbody weight/day. This
millionfold range ofpotency is the context in which the
tenfolddifferences which aresometimesobservedbetween
the potency of the same agent in different rodent
species should be viewed. It is also the context in which
different statistical approaches to estimating TD50 val-
ues should be viewed.
An obvious question to address with this list ofTD50
values is to what extent these values are predictable
from short-term test results. Ofcourse, there are many
qualitatively different carcinogens, and no single short-
termtest is likely to assess all ofthese differenttypes of
agent. For example, it is obvious that a mutagenicity
test can be expected to indicate the carcinogenic haz-
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ards only of chemicals that are carcinogenic chiefly by
virtue oftheirmutagenicity, orby virtue ofsome closely
alliedproperty Amutagenicitytestis, therefore, unlikely
to be of much assistance in assessing the carcinogenic
effects of such agents as asbestos or phorbol esters or
hormone replacement therapy, and will have nothing to
say regarding such important factors as obesity or
delayed maternity. Indeed, no single in vitro test is ever
likely to rank a series ofqualitatively different determi-
nants of cancer rates in order of human importance of
agents, although within one class (e.g., some subset of
the mutagens, perhaps) it might be possible to develop
tests which usefully predict at least the orders of
magnitude of their quantitative carcinogenicity.
Appendix
Not all experiments involve continuous daily expo-
sure throughout the test animal's lifetime, and many
experiments do not continue for the full standard
lifespan. In addition, few published papers report
sufficient details on tumor occurrence to allow proper
actuarial analysis. We have therefore had to adopt
conventions regarding the estimation of the TD50 from
"nonstandard" data. These conventions are described in
this appendix, together with numerical algorithms for
their implementation. There is, ofcourse, little point in
the general reader examining the appendix in detail,
and no part ofit is intended as part of the definition of
the TD50.
The definition ofthe TD50 is "the dose rate (in mg/kg
body weight/day that, if administered chronically for a
standard period-the 'standard lifespan' ofthe species
-will halve the mortality-corrected estimate of the
probability of remaining tumorless throughout that
period. Quite apart from the need to define how long a
"standard lifespan" is, this definition of the TD50 is of
little practical use until we consider how parts per
million are to be converted to units of mg/kg body
weight/day, what to do when the experiment does not
continue for the full standard lifespan, what to do when
all the animals, including the controls, get tumors
spontaneously, and how to generalize the definition to
cover substances (like saccharin) where no practicable
dose can possibly give half the animals cancer.
Standard Lifespan
By convention, most of the chronic studies for rats
and mice currently conducted by the NCI/NTP are
begunwhen the test animals are 6 to 8 weeks ofage and
are terminated after 90 to 110 weeks on test; the
survivors are then killed and autopsied. In interpreting
data from the large number ofcareful studies that have
been published in the literature, it is convenient to
adopt an experiment time in the range of 90 to 110
weeks as the conventional "lifespan" for rats and mice.
For simplicity, we have adopted 2 years (104 weeks), a
value that appears frequently in the literature, as the
conventional lifespan for rats and mice in our Carcino-
genic Potency Database. Based on values given in the
literature, we have adopted 2 years as the conventional
lifespan for hamsters, 11 years as that for dogs and 20
years as that for rhesus, cynomolgous, and African
green monkeys.
The TD50 for rats and mice is thus the dose rate in
mg/kg body weight/day that, if administered for 2
years, will halve the actuarially adjusted proportion of
tumorless survivors at that time. Ad hoc methods will
later be suggested forestimatingthis TD50 from experi-
ments that were terminated before or after 2 years.
(Note that it would not suffice to consider only those
tumors which were detected in the first 104 weeks of a
110 week experiment, because then one would miss the
"incidental" tumors that were present at week 104 but
not detected until later.)
Estimation of Mean (Lifelong)
mg/kg Body Weight/day
With regard to TD50, there are not at present
sufficient data to determine whether mg/kg body
weight/day, mg/m2surfacearea/day, mg/day, mg/lifetime,
or ppm in the food or water will be the measure ofdose
that is most consistent among different species of
laboratory animal, or between short-lived and long-
lived species such as mice and men. The decision to
define the TD50 in terms of mg/kg body weight/day is
therefore largely arbitrary, and may require revision in
thefuturewhenmoredatabecomeavailableonquantita-
tive interspecies differences in carcinogenicity. If, for
thepresent, mg/kgbodyweight/dayischosenprovisionally,
conventions must be established to convert ppm in food
or water into mg/kg body weight/day, and to deal with
experiments where active treatment is discontinued
some time before the experiment is terminated.
Even for a single experiment, there is no constant
factor that exactly converts ppm in food or water to
mg/kg body weight/day, because both food intake and
body weight vary with age (and, in some experiments,
with treatment). However, by assuming 100% absorp-
tion and adopting a set of standard values for each
sex/species group which includes factors for daily food,
water and air intake and average weight, we convert
dose to mg/kg body weight/day. We know that these
conversion factors will not be exactly correct, but,
because their derivation considered weights and water
intakes found in several sources in the literature, they
are unlikely to be substantially in error. Details ofthese
conversion factors are given in the following paper (4).
In some experiments, treatment is stopped before
the scheduled end of the experiment, and the mean
dose rate over the whole experimental period is there-
fore lower than the dose rate given during active
treatment. For example, animals that receive 180 ppm
in their food for 15 months in an experiment scheduled
to end after 18 months could be considered to receive
approximately an equivalent treatment to animals that
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received 150 ppm (180 x 15/18) ppm over the whole
experiment period. This convention is probably as good
as any, unless most of the treated animals developed
tumors before treatment ceased, and we have therefore
adopted it in the Carcinogenic Potency Database.
Correction for Experiments Which Terminate
Prior to or After the Standard Lifespan
In an experiment which is terminated before the
standard lifespan, the numbers oftumors found will be
reduced, and the dose rate d needed to halve the
proportion of tumorless animals at the end of the
reduced period ofobservation will then be greater than
the true TD50. For this reason, one might estimate the
true TD50 asfd,f2d orf3d, where we definef = (dura-
tion ofexperiment)/(standard lifespan). The experimen-
tal results of Druckrey (8) and Lee and O'Neill (9)
suggest that the TD50 will be something like f2d or
perhaps evenf3d.
The standard lifespan has been defined to be 24
months for mice and rats. Since most good experiments
are scheduled to continue for at least 18 months, fwill
usually be at least 0.75, and it will therefore not matter
greatly whether we correct by f2 or f3. To avoid
overcorrection, we recommend that the "corrected"
TD50 be estimated as f2d, and we have adopted this
convention in the Carcinogenic Potency Database.
Similarly, if an experiment is continued longer than
the standard lifespan (f > 1), then we recommend that
the dose rate d needed to halve the proportion of
tumorless animals at the end of the extended period of
observation be calculated and the TD50 again be esti-
mated asf2d. (Since few experiments continue past 110
weeks, this correction will not have a large effect.)
Superficially, it would look much more "statistically
respectable" to fit a Weibull distribution, in which the
incidence rate of tumors was assumed to be propor-
tional to (duration-w)k, to the experimental results and
to estimate the results oflifelong exposure accordingly.
Since there are two parameters, a misleadingly excel-
lentfitisassured, but, infact, degeneracies betweenthe
parameters of this formula (and, likewise, between the
parameters of various alternative formulae) exist that
can cause unpredictable errors (10). This is less true of
the suggested routine use of the correction factorf2.
For example, let us consider an experiment in which
the surviving animals (mice or rats) were sacrificed
after 20 months on test. The TD50 calculated on the
basis of 20 months is then multiplied by the correction
factorf2 = (20/24)2 = 0.69toyieldtheTD50based onthe
"standard" lifespan for the species. Further details of
this convention are given in the accompanying paper (4).
Inclusion of Incidental Tumors
When animals die of nonneoplastic disease, or when
they are finally sacrificed, some will be found at autopsy
to have tumors that may not have been discovered for
several weeks or months ifthe animals had lived on. In
general, actuarial methods should not be applied to
"incidental" tumors (3); however, applying these death-
rate methods to all tumors will usually lead to only a
smallerror (decrease in estimated probability ofremain-
ing tumorless) being made with experiments which end
with a terminal sacrifice ifall that is wanted is the final
proportion of tumorless animals. In practice, these
incidental tumors are very important because they may
be numerous enough to constitute an appreciable pro-
portion ofthe information yielded by the whole experi-
ment. Moreover, very few experimental reports, not
eventhe otherwise excellent NCI/NTPrecords, attempt
to distinguish between incidental and nonincidental
tumors. The large number ofanimals suddenly found to
have tumors in the final week of an experiment which
ends with the sacrifice of all survivors may cause
difficultiesifWeibull, lognormal, orsomeother paramet-
ric statistical method is used to analyze the data, but
need cause no difficulties if nonparametric methods
are used.
Selection of Tumor Sites
on Which to Base TD50
Consider an experiment comparing a control group
and one treated group in which there are two tumor
types, only one of which is affected by treatment, and
where times to tumor are exponentially distributed.
Suppose further that, in the control group, the actuari-
ally adjusted cumulative incidence of tumors at the
affected site is 5% and of all tumor-bearing animals is
50%. If the treatment increases the cumulative inci-
dence at the affected site to 15%, this will result in a
55.3%cumulative incidenceofalltumorbearinganimals.
The TD50 calculated only for the tumor site affected by
treatment will be the same as that calculated for all
tumor bearing animals. The advantage of restricting
our interest to a single tumor site is that it may yield an
analysis which appears more relevant because it is not
affected by the random occurrence ofunrelated tumors.
In addition, there is greater statistical power associated
with detectingthe 5 to 15% increase than with detecting
the 50 to 55.3% increase. In fact, for groups of 50
animals, the expected power is more than four times
greater at the lower incidence.
The disadvantage, unless it is absolutely clear which
tumors are dose-dependent and which are not, is that
such selection automatically biases the comparison of
treated with controlanimals, and therebytends toexag-
gerate the carcinogenic potency of the test substance.
Moreover, the intuitive reasons for looking only at
affected sites are already satisfied by the original
definition ofthe TD50 (involving ahalving ofthe number
of tumorless survivors), because tumors that have a
similar age-specific incidence in all groups of animals,
treated or untreated, do not systematically affect the
TD50.
If a treatment causes tumors at more than one site,
6NUMERICAL DESCRIPTION OF CARCINOGENIC POTENCY
then the site that is most strongly affected is usually
affected much more than the other site(s), and the TD50
can be adequately approximated by studying tumors at
that single site. If, therefore, apublished reportdescribes
tumor incidence at certain sites or groups of sites and
none ofthese sites or groups is exactly what is wanted,
it is probably best to restrict attention to that reported
site or group of sites with the most highly statistically
significant carcinogenic effect. As remarked above, in
cases ofmarginal statistical significance, this procedure
will exaggerate the carcinogenicity ofthetest substance,
but this will not generally happen when there is a very
marked carcinogenic effect. Details of our selection of
tissue and tumor types for the Carcinogenic Potency
Database are given in the accompanying paper (4).
Statistical Methods for Estimating
the TD50 When Time-to-Tumor Data
Are Available
Different statisticians would undoubtedly devise dif-
ferent statistical methods for estimating the TD50. One
simple way would be to calculate for each group the
probability P of remaining tumorlesst and to plot a
graph of these probabilities against dose rate. With P
plotted on a log2 scale, there will then be a unit change
in log2 P as we go from zero dose to the TD50 (Fig. 1).
Itmay be that such agraphwillyield approximately a
straight line, for this is predicted by certain rather
simplemultistage modelsforcancerinduction. However,
otherequally plausible multistage models do not predict
straight lines, and so the expectation that the line
might be straight must not distort the interpretation of
the actual plotted data.
One simple way to construct a line through such data
is to estimate the variance ofeach log2 P value (e.g., by
the Greenwood formula (3,11) and then to find which
"acceptable" straightlineminimizestheinverse-variance-
weighted sum ofsquared deviations ofthe datafromthe
line. "Acceptable" here means only that the dose-
response relationship shall have nonnegative slope (b)
and nonnegative intercept (a), so the set of acceptable
lines is somewhat constrained. Once a line has been
derived, it is easy to read the TD50 from it; the slope b
equals 1/TD50, and the confidence interval for the slope
yields aconfidence intervalfor 1/TD50. The only unusual
feature about confidence intervals for 1/TD50 is that if
the lower limit is zero or less, than there is no upper
confidencelimitfortheTD50(i.e., wecannotbeconfident
that the substance has any carcinogenic effect). In
certain cases, the TD50 may represent an impossibly
large dose for compounds exhibiting no carcinogenicity;
however, we are able to compute alowerconfidence limit
for such compounds.
tFormally, P is the actuarially adjusted probability of remaining
completely free of any fatal or incidental tumor throughout the
standard lifespan.
0
0 50 100
Average daily dose-rote
(mg/kg body wt/doy)
150
XBL829-41 16
FIGURE 1. Graph of-log2P against averagedailydose rate, whereP
= actuarially adjusted probability of remaining tumorless, for
NCI/NTP experiment of tris(2,3-dibromopropyl) phosphate in
male mice, composite of tissue and tumor pathologies considered
positive. Standard errors of -log2 P are indicated and were esti-
mated as in Pike and Roe (11).
An alternative to deriving the "best" acceptable
straight line by least squares is to derive it by an
adaptation (see below) of the methods of Cox (12) for
analyzing censored data. Cox's methods are, in various
minor ways, preferable for the specific purpose of
plotting a straight line through a graph of -log2 P and
studying its slope, but they are obviously not essential,
and for most purposes inverse-variance-weighted least
squares lines will be about as good.
Analysis when Time-to-Thmor Data
Are Available: Outline of the Statistical
Principles Underlying Cox's Methods
Cox (12) pointed out that a likelihood function which
allowed standard methods of statistical inference to be
used could be derived from a conditional argument:
given the numbers of animals at risk of cancer in each
group at the start ofeach week, whatis the likelihood of
the events that occurred in that week? This conditional
argument allows very general pa,rameterization of the
time-dependence of risk, usually without material loss
of statistical efficiency. We use Cox's arguments to fit
the family of models
10g2 Pij =-h[a + b(dosei)]
where a, b, and h1, . . . , ht are parameters of the
model which are to be fitted subject to a
- 0, b
- 0, and
each hj
: 0; and Pij is the conditional probability of a
disease-free animal in group i at time j remaining
disease-free until time j + 1. Clearly, such a model is
degenerate, in that, without changing the predictions
for logPij, the hj could all be multiplied by any positive
constant if a and b were also divided by that constant.
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We must therefore normalize thehjin some way, and one
can then usually find unique values a, b, and hj that
maximize Cox's (12) conditional likelihood; b then esti-
mates 1/TD50. Although computationally tedious, the
advantages of such methods are that they deal quite
naturally with the sudden large numbers oftumors that
may be found in the final week of an experiment when
all the survivors are killed and autopsied; they are
asymptotically efficient against Weibull alternatives;
they are robust if Weibull alternatives do not exactly
govern the data; and they are rank invariant. Further
details of our methods for finding b and its confidence
limits with this Cox model have been given by Sawyer et
al. (13).
Analysis When Actuarial Correction
Is Impossible
Often, animal carcinogenicity studies are reported
simply in terms of the numbers of tumor-bearing
animals in each group; actuarially adjusted numbers are
not given, nor are sufficient details of survival and
tumor times provided to allow actuarial calculations. As
has already been noted, a carcinogenic treatment that
also causes deaths by nonneoplastic toxicity may cause
so many ofthe treated animals to die prematurely that
the crude proportion of tumor-bearing animals is much
smaller than it would have been ifactuarial analysis had
been possible. This effect is usuallymost marked among
thehigh-dose animals, andthisthenresultsinunderesti-
mation of any index of carcinogenicity.
When each data point is simply abinomial proportion,
wefit the straight line -log2 P = a + bdbyaconstrained
(a
- 0, b , 0)maximumlikelihoodfit. Minordifficultiesof
programming are caused by the possibility that the
constrained maximum likelihood value (or one of the
confidence limits) may actually lie on one of the con-
straints a = 0 or b = 0, but these difficulties can, with
due care, be circumvented.
Some authors who do not give full time-to-tumor data
nevertheless cite some denominator (e.g., numbers of
survivors in each group when the first tumor in the
experiment arose) that makes partial allowance for the
effects ofintercurrent mortality on the numbers at risk
of cancer. A crude percentage of tumorless animals
based on such a reduced denominator may not be ideal,
but it is often preferable to an even cruder percentage
based on the original denominator, as it does at least
make some allowance for the effects of premature
deaths on the numbers ofanimals that develop tumors.
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